Wells Fargo Maintains Equal-Weight on Ventyx Biosciences, Lowers Price Target to $3
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Derek Archila has maintained an Equal-Weight rating on Ventyx Biosciences (NASDAQ:VTYX) but reduced the price target from $8 to $3.

December 19, 2023 | 1:30 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Wells Fargo analyst Derek Archila maintains an Equal-Weight rating on Ventyx Biosciences but cuts the price target from $8 to $3.
The reduction in price target by Wells Fargo is likely to negatively impact investor sentiment towards Ventyx Biosciences in the short term, as it suggests a lower valuation of the company's stock than previously estimated. This could lead to a decrease in the stock price as the market adjusts to the new price target.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100